Category: Delcath Systems Inc.
Delcath Systems adds 2 German research centers to a Phase II clinical trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer.
Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer.
Here's a look at some of the top Wall Street stories for medical device companies this week.
Wall Street flees from troubled Delcath Systems after the cancer-treatment devices maker proceeds with a 1-to-16 reverse stock split.
Shares of Delcath (NSDQ:DCTH) dropped more than 18% by the early afternoon today after the company proceeded with a 1-to-16 reverse stock split.
Here's a look at some of the top personnel stories for medical device companies this week.
The proxy war over control of the board at ConMed turned ugly this week after serious allegations surfaced against 1 of the medical device company's nominees for director.
Becton Dickinson & Co.
, Boston Scientific
, Carlyle Group
, ConMed Corp.
, Coppersmith Capital Management
, Cutera Inc.
, Delcath Systems Inc.
, Johnson & Johnson
, Kaiser Permanente Ventures
, Merck KGaA
, Millipore Corp.
, National Quality Forum
, Ortho-Clinical Diagnostics
, Premier Inc.
, Stryker Corp.
, Varian Medical Systems
, Voce Capital Management
Spinal devices maker Vexim appoints as its director of marketing Sandrine Carle, a veteran of spinal operations at medtech giant Medtronic.
French spinal devices maker Vexim (EPA:ALVXM) this month welcome Medtronic (NYSE:MDT) veteran Sandrine Carle as its director of marketing.
Neuro Kinetics named former Zoll Medical executive Michael Saporito as CFO.
Neuro Kinetics appointed Michael Saporito as its new CFO.
Saporito joins the Pittsburgh-based medical device company after years with LifeVest, which he helped turn around before the company was bought out by Zoll Medical.
Amid a flurry of layoffs and restructuring after failed attempts to win FDA approval, New York device maker Delcath Systems aims for a $7.5 million funding round.
New York's Delcath Systems (NSDQ:DCTH) is looking to raise about $7.5 million through sales of common stock, planning on using the funds for working capital, commercialization efforts, clinical trials and other "general corporate purposes."